论文部分内容阅读
目的 构建靶向性基因治疗载体pcDNA3.1(-)CMV·Egr—1CDglyTK并进行转染研究。方法采用PCR、RT—PCR、融合PCR、酶切、连接等技术构建pcDNA3.1(-)CMV·Egr—1CDglyTK表达载体,成功转染鼻咽癌CNE—2细胞,绘制细胞相对存活率曲线,初步研究该载体在前体药物干预下对CNE—2细胞生长的影响。结果 表达pcDNAA3.1(-)CMV·Egr—1CDglyTK的CNE—2细胞在5—FC/GCV干预下生长受到抑制。结论pcDNA3.1(-)CMV·Egr—1CDglyTK可作为鼻咽癌基因治疗的载体。
Objective To construct a targeted gene therapy vector pcDNA3.1 (-) CMV · Egr-1CDglyTK and transfection study. Methods The pcDNA3.1 (-) CMV · Egr-1CDglyTK expression vector was constructed by PCR, RT-PCR, fusion PCR, restriction enzyme digestion and ligation and successfully transfected into nasopharyngeal carcinoma CNE-2 cells. The relative cell viability The effect of this vector on the growth of CNE-2 cells under the influence of prodrugs was studied preliminarily. Results The growth of CNE-2 cells expressing pcDNAA3.1 (-) CMV · Egr-1CDglyTK was inhibited by 5-FC / GCV intervention. Conclusion pcDNA3.1 (-) CMV · Egr-1CDglyTK can be used as a gene therapy vector for nasopharyngeal carcinoma.